DexCom, Inc. (NASDAQ:DXCM) Position Raised by Stonebrook Private Inc.

Stonebrook Private Inc. increased its stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 96.3% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,370 shares of the medical device company's stock after acquiring an additional 4,106 shares during the quarter. Stonebrook Private Inc.'s holdings in DexCom were worth $572,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Larson Financial Group LLC boosted its holdings in DexCom by 40.5% in the fourth quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock worth $37,000 after acquiring an additional 137 shares in the last quarter. Nia Impact Advisors LLC raised its stake in shares of DexCom by 1.4% in the fourth quarter. Nia Impact Advisors LLC now owns 9,850 shares of the medical device company's stock worth $766,000 after purchasing an additional 140 shares during the last quarter. Level Four Advisory Services LLC raised its stake in shares of DexCom by 1.1% in the fourth quarter. Level Four Advisory Services LLC now owns 13,196 shares of the medical device company's stock worth $1,026,000 after purchasing an additional 150 shares during the last quarter. Covestor Ltd raised its stake in shares of DexCom by 15.6% in the fourth quarter. Covestor Ltd now owns 1,109 shares of the medical device company's stock worth $86,000 after purchasing an additional 150 shares during the last quarter. Finally, TD Private Client Wealth LLC raised its stake in shares of DexCom by 62.8% in the fourth quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock worth $34,000 after purchasing an additional 167 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors.

DexCom Price Performance

Shares of DXCM stock traded down $1.94 during mid-day trading on Friday, reaching $83.52. The stock had a trading volume of 1,067,565 shares, compared to its average volume of 4,410,929. The company has a market cap of $32.75 billion, a P/E ratio of 62.35, a price-to-earnings-growth ratio of 1.81 and a beta of 1.44. The business has a 50-day simple moving average of $84.31 and a 200 day simple moving average of $79.97. DexCom, Inc. has a 12-month low of $57.52 and a 12-month high of $117.19. The company has a current ratio of 1.50, a quick ratio of 1.32 and a debt-to-equity ratio of 0.55.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The medical device company reported $0.32 EPS for the quarter, missing the consensus estimate of $0.33 by ($0.01). DexCom had a net margin of 12.90% and a return on equity of 30.05%. The business had revenue of $1.04 billion during the quarter, compared to analysts' expectations of $1.02 billion. During the same quarter last year, the firm earned $0.32 EPS. The firm's quarterly revenue was up 12.5% compared to the same quarter last year. On average, sell-side analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently commented on DXCM. Citigroup reiterated a "buy" rating and set a $102.00 price objective (up previously from $82.00) on shares of DexCom in a research report on Thursday, May 22nd. The Goldman Sachs Group began coverage on DexCom in a research report on Friday, May 30th. They set a "buy" rating and a $104.00 price objective for the company. Piper Sandler reduced their price objective on DexCom from $100.00 to $90.00 and set an "overweight" rating for the company in a research report on Friday, May 2nd. Wall Street Zen cut DexCom from a "buy" rating to a "hold" rating in a research report on Sunday, June 29th. Finally, Mizuho assumed coverage on DexCom in a research report on Thursday, April 10th. They issued an "outperform" rating and a $85.00 price target for the company. Five research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat, DexCom currently has a consensus rating of "Moderate Buy" and an average target price of $98.50.

Insider Buying and Selling

In related news, Director Mark G. Foletta sold 2,750 shares of the firm's stock in a transaction on Monday, June 16th. The stock was sold at an average price of $83.13, for a total transaction of $228,607.50. Following the transaction, the director directly owned 56,621 shares in the company, valued at $4,706,903.73. This trade represents a 4.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Nicholas Augustinos sold 3,672 shares of the firm's stock in a transaction on Monday, June 16th. The stock was sold at an average price of $82.80, for a total value of $304,041.60. Following the transaction, the director owned 33,411 shares in the company, valued at $2,766,430.80. This trade represents a 9.90% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 27,190 shares of company stock valued at $2,281,732. Insiders own 0.32% of the company's stock.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.